Myriad Genetics Inc (MYGN)

Profile

• URL: https://www.myriad.com
• Investor Relations URL: https://myriad.com/news-center/investor-information/
• HQ State/Province: Utah
• Sector: Healthcare
• Industry: Diagnostics & Research
• Equity Style: Small Cap/Value
• Next Earnings Release: Feb. 05, 2021
• Last Earnings Release: Nov. 09, 2020
• Next Ex-Dividend Date: N/A
• Last Ex-Dividend Date: N/A
• Description: Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual’s risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.